evidence was provided by the detection of the TEl-AML1 (now known as EVT6-RUNX1) fusion gene which results from the t(12;21)(p13;q22) and which occurs only in primary and cultured BCP cells (including cell line REH); 4 all three cell cultures examined showed this genetic abnormality ( Figure 2) . Cytogenetic analysis has shown that the TEL-AML1 fusion is generated in REH by a unique four-way translocation, t(4;12;21;16) 4 which we have now confirmed in WSU-CLL. Taken together, WSU-CLL is definitely only a subclone of cell line REH and is hence a BCP cell line.
It has been reported that there are significant phenotypic differences between WSU-CLL and REH. For instance, while WSU-CLL grows very well in SCID mice, REH cells allegedly do not grow in these animals. However, a literature search shows that different investigators were able successfully to heterotransplant REH cells into nude and SCID mice. 6 Nevertheless, it is well known that subclones derived explicitly or inadvertently from their parental cultures can develop quite divergent phenotypic features. A good case in point is the widely distributed cell line K-562 for which quite dramatic phenotypic differences between subcultures with regard to growth kinetics, cloning efficiency and hemoglobin production have been noted. 7 A large panel of K-562 sublines shared several common surface antigens but expressed a marked diversity and variability of other markers. 8 In this context, we examined the expression of a panel of immunomarkers on the cell lines WSU-CLL, REH (ATCC) and REH (DSMZ) ( Table 1 ). It became evident that these genotypically identical cell lines express some phenotypic markers to various extents, eg CD20, CD34, CD138 ( Figure 3) .
In summary, different approaches have revealed that the WSU-CLL cell line is indeed the REH cell line and most likely resulted from an inadvertent cross-contamination during cell culture at the original source, presumably during the attempts to establish a B-CLL cell line. Hence, WSU-CLL is a subclone of BCP-ALL cell line REH and it is clearly inappropriate to use WSU-CLL as a model for B-CLL. TO THE EDITOR Treatment of relapsed AML is difficult, especially if remission duration was short, if it is later than first relapse, if karyotype is unfavourable or if the patient is not eligible for intensive treatment. We report a case of a 76-year-old female patient presenting with all these unfavourable predictors. Remarkably, this patient entered a third complete remission (CR) following a single dose of gemtuzumab ozogamicin (CMA-676), and CR duration with low-dose interleukin-2 (IL-2) maintenance now exceeds 11 months.
The patient was first diagnosed with AML, FAB M5, with t(1;21)(q21;q22) in October 1998. The patient was treated with cytarabine, daunorubicin and the multidrug resistance modulator PSC 833 for induction resulting in CR, followed by two consolidation chemotherapies which consisted of cytarabine, daunorubicin and PSC 833 (consolidation 1), and cytarabine, mitoxantrone and etoposide (consolidation 2). Treatment was complicated by profuse peranal bleeding during pancytopenia following induction.
Fourteen months later the patient was readmitted with first relapse of AML. Treatment with mitoxantrone, etoposide and cytarabine, resulted again in CR. One cycle of consolidation therapy was adminis- Another 6 months later the patient was readmitted with her second recurrence of AML and t(1;22)(p11;p11) was observed as second cytogenetic aberration. Treatment with oral low-dose melphalan (2 mg/day) was initiated. This treatment has been shown to be well tolerated and effective in some patients with secondary AML. 1 However, re-evaluation 4 weeks later demontrated progressive pancytopenia, increased marrow blast counts and del(1)(q21) as the third cytogenetic abnormality.
The patient was well informed about her prognosis and agreed on a single dose of CMA-676 (9 mg/m 2 ), although administration of two doses is generally recommended.
2 CMA-676 is a humanized murine anti-CD33 antibody linked to the potent tumor antibiotic Nac-gamma calicheamicin. Calicheamicin exerts its toxic effects only after cleavage from the antibody following incorporation into CD33-positive cells; toxin bound to antibody is inactive.
3 CD33 is brightly expressed on most AML blasts and on some myeloid precursors, but scarcely expressed in non-myeloid tissues and absent on hematopoietic stem cells. 4 Distribution of CD33 antigen and properties of the immunotoxin explain anti-AML selectivity of CMA-676 compared to conventional chemotherapeutic drugs. In 142 patients with CD33-positive AML in first relapse a 30% overall remission rate was achieved. 5 In our patient, leukemic blasts highly expressed the CD33 antigen and treatment with CMA-676 was effective and well tolerated: bone marrow aspirate on day 40 showed complete clearance of leukaemic blasts. The major adverse reaction was prolonged pancytopenia asso-ciated with pulmonary infiltrates, which were responsive to combined antibiotic and antimycotic therapy. Haematological reconstitution was achieved at day 48 for leukocytes (Ͼ3 × 10 9 /l) and at day 54 for platelets (Ͼ20 × 10 9 /l, without substitution). Substitution was with 17 packed red blood cell concentrates and 23 pooled platelet concentrates. CR with platelets Ͼ100 × 10 9 /l was obtained 64 days after CMA-676.
Due to high risk of relapse, we started outpatient maintenance with subcutaneous IL-2.
IL-2 has the potential to enhance cytotoxic activity of NK and cytotoxic T cells against AML blasts.
6 Clinical trials have shown that treatment with IL-2 may be beneficial in the therapy of AML. 7 The initial schedule with 5 million units of IL-2 on 5 consecutive days per month, was reduced to 4 Mio U and 3 Mio U in consecutive cycles due to flu-like symptoms during treatment days. The latter dose was well tolerated, and our patient is still in complete remission 11 months post CMA-676 induction.
This case illustrates that novel treatment options such as CMA-676 followed by IL-2 maintenance open therapeutic perspectives and may save vital time of life for elderly patients even if conditions are strongly predictive of unfavourable outcome. We suggest that this approach deserves further study.
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Department TO THE EDITOR Hematopoietic growth factors (HGF), particularly G-CSF, are widely used in hematopoietic malignancies to reduce the duration of neutropenia induced by chemotherapy and its subsequent infectious complications. In acute myeloid leukemia (AML), G-CSF or GM-CSF has been used to reduce the duration of neutropenia after induction or consolidation therapy. The benefit of such strategies remains controversial: most studies report a shorter duration of neutropenia with a lower incidence of infections in the HGF arms, but no evidence of reduced mortality. 1 When HGF is administered concomitantly with chemotherapy, it recycles leukemic cells and may increase their chemosensitivity. In some studies, patients treated with G-CSF or GM-CSF showed a statistically higher rate of complete remission with improvement of DFS but not overall survival.
1,2 These studies demonstrate that G-CSF or GM-CSF may have an anti-leukemic effect. In fact, leukemic cells display HGF receptors and some authors have shown G-CSF-induced apoptosis of leukemic cell. 3 Comorbid affections due to advanced age or life-threatening infections associated with leukemia can sometimes postpone chemotherapy. Hematopoietic growth factors may be used to temporarily increase the polymorphonuclear neutrophil (PMN) count in cases of severe infection. 
